Solid Biosciences Inc. (SLDB) 10-Year Financial Performance & Capital Metrics

SLDB • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSolid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$127M -25.1%
Net Income -$125M -29.9%
EPS (Diluted) -3.06 +36.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -94.57% -66.5%
ROIC -121.68% -27.2%
Debt/Equity 0.18 -15.2%
Interest Coverage -381.55

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM16.42%

ROCE

10Y Avg-68.65%

5Y Avg-60.13%

3Y Avg-61.81%

Latest-84.01%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	13.62M	8.09M	0	0
Revenue Growth %	-	-	-	-	-	-	-	-0.41%	-1%	-
Cost of Goods Sold+	0	56K	0	1.57M	2.82M	3.92M	0	0	2.58M	2.46M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-56K	-448K	-1.57M	-2.82M	-3.92M	13.62M	8.09M	-2.58M	-2.46M
Gross Margin %	-	-	-	-	-	-	1%	1%	-	-
Gross Profit Growth %	-	-	-7%	-2.5%	-0.8%	-0.39%	4.47%	-0.41%	-1.32%	0.05%
Operating Expenses+	6.56M	25.58M	54.86M	75.69M	119.32M	82.54M	85.87M	114.55M	101.73M	127.27M
OpEx % of Revenue	-	-	-	-	-	-	6.3%	14.15%	-	-
Selling, General & Admin	2.37M	5.46M	14.95M	17.72M	24.58M	21.58M	27.14M	28.95M	27.75M	33.3M
SG&A % of Revenue	-	-	-	-	-	-	1.99%	3.58%	-	-
Research & Development	4.19M	20.12M	39.91M	57.97M	94.74M	64.88M	58.74M	78.42M	76.56M	96.43M
R&D % of Revenue	-	-	-	-	-	-	4.31%	9.69%	-	-
Other Operating Expenses	0	0	0	270K	0	-3.92M	0	7.18M	-2.58M	-2.46M
Operating Income+	-6.56M	-25.58M	-54.86M	-75.69M	-119.32M	-86.46M	-72.25M	-106.45M	-104.31M	-129.73M
Operating Margin %	-	-	-	-	-	-	-5.3%	-13.15%	-	-
Operating Income Growth %	-	-2.9%	-1.14%	-0.38%	-0.58%	0.28%	0.16%	-0.47%	0.02%	-0.24%
EBITDA+	0	-25.52M	-54.41M	-74.12M	-116.49M	-82.54M	-69.29M	-104.04M	-101.73M	-127.27M
EBITDA Margin %	-	-	-	-	-	-	-5.09%	-12.85%	-	-
EBITDA Growth %	-	-	-1.13%	-0.36%	-0.57%	0.29%	0.16%	-0.5%	0.02%	-0.25%
D&A (Non-Cash Add-back)	6.56M	56K	448K	1.57M	2.82M	3.92M	2.96M	2.41M	2.58M	2.46M
EBIT	-6.66M	-25.58M	-54.86M	-74.8M	-119.32M	-88.29M	-72.25M	-99.27M	-96.02M	-124.36M
Net Interest Income+	0	0	0	0	1.58M	115K	64K	2.62M	7.14M	9.13M
Interest Income	3K	369K	219K	619K	1.58M	115K	64K	2.62M	7.14M	9.47M
Interest Expense	0	0	0	0	0	0	0	0	0	340K
Other Income/Expense	-100K	1.8M	1.68M	889K	2.1M	-1.83M	66K	20.47M	8.3M	5.03M
Pretax Income+	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Pretax Margin %	-	-	-	-	-	-	-5.3%	-10.62%	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.96%	0.91%	0.98%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.38M	-21.54M	-52.12M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Net Margin %	-	-	-	-	-	-	-5.3%	-10.62%	-	-
Net Income Growth %	-	-2.38%	-1.42%	-0.44%	-0.57%	0.25%	0.18%	-0.19%	-0.12%	-0.3%
Net Income (Continuing)	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	47.59M	46.47M	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.97	-16.80	-24.26	-33.73	-43.05	-25.50	-10.14	-10.10	-4.83	-3.06
EPS Growth %	-	-2.38%	-0.44%	-0.39%	-0.28%	0.41%	0.6%	0%	0.52%	0.37%
EPS (Basic)	-4.97	-16.80	-24.26	-33.73	-43.05	-25.50	-10.14	-10.10	-4.83	-3.06
Diluted Shares Outstanding	1.28M	1.28M	2.15M	2.22M	2.69M	3.46M	7.12M	8.51M	19.88M	40.82M
Basic Shares Outstanding	1.28M	1.28M	2.15M	2.22M	2.69M	3.46M	7.12M	8.51M	19.88M	40.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.7M	39.97M	70.66M	128.64M	86.3M	158.9M	222.61M	219.64M	129.73M	157.3M
Cash & Short-Term Investments	55.39M	37.66M	69.09M	122.46M	83.52M	154.74M	207.78M	213.72M	123.64M	148.92M
Cash Only	28.59M	7.68M	52.08M	86.37M	76.04M	154.74M	119.14M	155.38M	74.02M	80.23M
Short-Term Investments	26.79M	29.98M	17.01M	36.1M	7.48M	0	88.64M	58.34M	49.63M	68.69M
Accounts Receivable	0	0	0	0	0	0	110K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	2.95	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	88K	235K	613K	1.81M	1.49M	1.48M	8.71M	3M	2.11M	1.65M
Total Non-Current Assets+	0	664K	5.54M	10.96M	17.17M	12.27M	9.77M	40.61M	35.2M	31.36M
Property, Plant & Equipment	0	452K	2.43M	10.42M	16.63M	11.73M	7.6M	38.61M	33.16M	29.04M
Fixed Asset Turnover	-	-	-	-	-	-	1.79x	0.21x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	212K	3.11M	536K	536K	536K	2.16M	2.01M	2.04M	2.32M
Total Assets+	55.7M	40.64M	76.19M	139.6M	103.47M	171.17M	232.38M	260.25M	164.94M	188.66M
Asset Turnover	-	-	-	-	-	-	0.06x	0.03x	-	-
Asset Growth %	-	-0.27%	0.88%	0.83%	-0.26%	0.65%	0.36%	0.12%	-0.37%	0.14%
Total Current Liabilities+	13.92M	6.87M	11.27M	12.48M	18.28M	24.48M	23.6M	22.51M	14.52M	30.26M
Accounts Payable	608K	2.98M	5.07M	3.69M	7.12M	3.27M	4.46M	3.24M	2.03M	4.24M
Days Payables Outstanding	-	19.45K	-	860.29	920.77	304.69	-	-	287.36	629.94
Short-Term Debt	0	0	0	173K	0	0	0	0	0	0
Deferred Revenue (Current)	0	345K	233K	1000K	0	1000K	1000K	0	0	0
Other Current Liabilities	13.06M	2.38M	4.17M	4.91M	3.63M	3.83M	3.12M	8.38M	5.95M	9.37M
Current Ratio	4.00x	5.82x	6.27x	10.31x	4.72x	6.49x	9.43x	9.76x	8.94x	5.20x
Quick Ratio	4.00x	5.82x	6.27x	10.31x	4.72x	6.49x	9.43x	9.76x	8.94x	5.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	61.7M	71.65M	124.18M	1.93M	5.15M	14.6M	568K	26.08M	23.94M	21.16M
Long-Term Debt	0	0	0	859K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	859K	5.15M	2.94M	568K	25.98M	23.94M	21.16M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	61.7M	71.65M	0	215K	0	1.3M	0	96K	0	0
Total Liabilities	75.62M	78.52M	135.45M	14.41M	23.42M	39.08M	24.17M	48.59M	38.46M	51.42M
Total Debt+	0	0	0	1.03M	7.07M	5.15M	2.06M	28.55M	26.27M	24.18M
Net Debt	-28.59M	-7.68M	-52.08M	-85.33M	-68.97M	-149.59M	-117.07M	-126.84M	-47.75M	-56.06M
Debt / Equity	-	-	-	0.01x	0.09x	0.04x	0.01x	0.13x	0.21x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-381.55x
Total Equity+	-19.93M	-37.89M	-59.26M	125.18M	80.05M	132.09M	208.21M	211.67M	126.48M	137.25M
Equity Growth %	-	-0.9%	-0.56%	3.11%	-0.36%	0.65%	0.58%	0.02%	-0.4%	0.09%
Book Value per Share	-15.54	-29.55	-27.57	56.44	29.80	38.15	29.25	24.87	6.36	3.36
Total Shareholders' Equity	-67.51M	-84.36M	-59.26M	125.18M	80.05M	132.09M	208.21M	211.67M	126.48M	137.25M
Common Stock	208K	558K	65.01M	35K	48K	87K	7K	20K	20K	40K
Retained Earnings	-67.71M	-84.94M	-124.26M	-199.06M	-316.28M	-404.57M	-476.76M	-562.74M	-658.75M	-783.45M
Treasury Stock	0	-558K	0	0	0	0	0	0	0	0
Accumulated OCI	-10K	23K	-13K	-5K	1K	0	-45K	-68K	15K	47K
Minority Interest	47.59M	46.47M	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.2M	-20.12M	-43.22M	-70.2M	-92.71M	-56.6M	-77.76M	-97.98M	-94.18M	-100.01M
Operating CF Margin %	-	-	-	-	-	-	-5.71%	-12.1%	-	-
Operating CF Growth %	-	-3.79%	-1.15%	-0.62%	-0.32%	0.39%	-0.37%	-0.26%	0.04%	-0.06%
Net Income	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Depreciation & Amortization	0	56K	448K	1.57M	2.82M	3.92M	2.96M	2.41M	2.58M	2.46M
Stock-Based Compensation	764K	1.47M	5.33M	5.96M	14.21M	11.63M	13.37M	7.54M	7.63M	10.52M
Deferred Taxes	0	505K	206K	0	0	0	1.21M	0	0	0
Other Non-Cash Items	108K	-1.16M	-459K	-86K	-277K	-20K	-81K	-18.25M	-2.03M	8.86M
Working Capital Changes	1.59M	2.79M	4.43M	-2.83M	7.75M	16.16M	-23.04M	-3.69M	-6.34M	2.85M
Change in Receivables	0	0	0	0	0	0	-110K	110K	0	0
Change in Inventory	0	0	0	0	0	0	-11.5M	0	0	0
Change in Payables	585K	2.21M	1.58M	-1.61M	3.78M	-3.43M	1.21M	-5.25M	-764K	2.21M
Cash from Investing+	-26.81M	-4.22M	10.55M	-26.76M	24.52M	6.6M	-91.09M	59.16M	9.69M	-16.09M
Capital Expenditures	0	-392K	-2.28M	-7.78M	-4.39M	-899K	-1.28M	-3.02M	-1.51M	-654K
CapEx % of Revenue	-	-	-	-	-	-	0.09%	0.37%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-26.81M	-165K	100K	-18.99M	24.52M	7.5M	-89.81M	600K	0	0
Cash from Financing+	51.59M	3.42M	77.08M	131.51M	57.88M	128.7M	134.99M	74.83M	3.12M	122.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	44.75M	0	-2.42M	-2.17M	8.55M	0	107K	203K	148K	794K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.2M	-20.51M	-45.5M	-77.97M	-97.1M	-57.5M	-79.05M	-100.99M	-95.69M	-100.67M
FCF Margin %	-	-	-	-	-	-	-5.8%	-12.48%	-	-
FCF Growth %	-	-3.88%	-1.22%	-0.71%	-0.25%	0.41%	-0.37%	-0.28%	0.05%	-0.05%
FCF per Share	-3.28	-16.00	-21.17	-35.15	-36.15	-16.61	-11.10	-11.86	-4.81	-2.47
FCF Conversion (FCF/Net Income)	0.66x	0.93x	0.83x	0.94x	0.79x	0.64x	1.08x	1.14x	0.98x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-226.91%	-114.24%	-83.24%	-42.43%	-40.96%	-56.79%	-94.57%
Return on Invested Capital (ROIC)	-	-	-	-	-351.47%	-	-147.19%	-90.74%	-95.67%	-121.68%
Gross Margin	-	-	-	-	-	-	100%	100%	-	-
Net Margin	-	-	-	-	-	-	-530.01%	-1062.28%	-	-
Debt / Equity	-	-	-	0.01x	0.09x	0.04x	0.01x	0.13x	0.21x	0.18x
Interest Coverage	-	-	-	-	-	-	-	-	-	-381.55x
FCF Conversion	0.66x	0.93x	0.83x	0.94x	0.79x	0.64x	1.08x	1.14x	0.98x	0.80x
Revenue Growth	-	-	-	-	-	-	-	-40.57%	-100%	-

Frequently Asked Questions

Growth & Financials

Solid Biosciences Inc. (SLDB) grew revenue by 0.0% over the past year. Growth has been modest.

Solid Biosciences Inc. (SLDB) reported a net loss of $167.1M for fiscal year 2024.

Dividend & Returns

Solid Biosciences Inc. (SLDB) has a return on equity (ROE) of -94.6%. Negative ROE indicates the company is unprofitable.

Solid Biosciences Inc. (SLDB) had negative free cash flow of $133.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Solid Biosciences Inc. (SLDB) 10-Year Financial Performance & Capital Metrics

SLDB • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$127M -25.1%
Net Income -$125M -29.9%
EPS (Diluted) -3.06 +36.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -94.57% -66.5%
ROIC -121.68% -27.2%
Debt/Equity 0.18 -15.2%
Interest Coverage -381.55

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM16.42%

ROCE

10Y Avg-68.65%

5Y Avg-60.13%

3Y Avg-61.81%

Latest-84.01%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	13.62M	8.09M	0	0
Revenue Growth %	-	-	-	-	-	-	-	-0.41%	-1%	-
Cost of Goods Sold+	0	56K	0	1.57M	2.82M	3.92M	0	0	2.58M	2.46M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-56K	-448K	-1.57M	-2.82M	-3.92M	13.62M	8.09M	-2.58M	-2.46M
Gross Margin %	-	-	-	-	-	-	1%	1%	-	-
Gross Profit Growth %	-	-	-7%	-2.5%	-0.8%	-0.39%	4.47%	-0.41%	-1.32%	0.05%
Operating Expenses+	6.56M	25.58M	54.86M	75.69M	119.32M	82.54M	85.87M	114.55M	101.73M	127.27M
OpEx % of Revenue	-	-	-	-	-	-	6.3%	14.15%	-	-
Selling, General & Admin	2.37M	5.46M	14.95M	17.72M	24.58M	21.58M	27.14M	28.95M	27.75M	33.3M
SG&A % of Revenue	-	-	-	-	-	-	1.99%	3.58%	-	-
Research & Development	4.19M	20.12M	39.91M	57.97M	94.74M	64.88M	58.74M	78.42M	76.56M	96.43M
R&D % of Revenue	-	-	-	-	-	-	4.31%	9.69%	-	-
Other Operating Expenses	0	0	0	270K	0	-3.92M	0	7.18M	-2.58M	-2.46M
Operating Income+	-6.56M	-25.58M	-54.86M	-75.69M	-119.32M	-86.46M	-72.25M	-106.45M	-104.31M	-129.73M
Operating Margin %	-	-	-	-	-	-	-5.3%	-13.15%	-	-
Operating Income Growth %	-	-2.9%	-1.14%	-0.38%	-0.58%	0.28%	0.16%	-0.47%	0.02%	-0.24%
EBITDA+	0	-25.52M	-54.41M	-74.12M	-116.49M	-82.54M	-69.29M	-104.04M	-101.73M	-127.27M
EBITDA Margin %	-	-	-	-	-	-	-5.09%	-12.85%	-	-
EBITDA Growth %	-	-	-1.13%	-0.36%	-0.57%	0.29%	0.16%	-0.5%	0.02%	-0.25%
D&A (Non-Cash Add-back)	6.56M	56K	448K	1.57M	2.82M	3.92M	2.96M	2.41M	2.58M	2.46M
EBIT	-6.66M	-25.58M	-54.86M	-74.8M	-119.32M	-88.29M	-72.25M	-99.27M	-96.02M	-124.36M
Net Interest Income+	0	0	0	0	1.58M	115K	64K	2.62M	7.14M	9.13M
Interest Income	3K	369K	219K	619K	1.58M	115K	64K	2.62M	7.14M	9.47M
Interest Expense	0	0	0	0	0	0	0	0	0	340K
Other Income/Expense	-100K	1.8M	1.68M	889K	2.1M	-1.83M	66K	20.47M	8.3M	5.03M
Pretax Income+	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Pretax Margin %	-	-	-	-	-	-	-5.3%	-10.62%	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.96%	0.91%	0.98%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.38M	-21.54M	-52.12M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Net Margin %	-	-	-	-	-	-	-5.3%	-10.62%	-	-
Net Income Growth %	-	-2.38%	-1.42%	-0.44%	-0.57%	0.25%	0.18%	-0.19%	-0.12%	-0.3%
Net Income (Continuing)	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	47.59M	46.47M	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.97	-16.80	-24.26	-33.73	-43.05	-25.50	-10.14	-10.10	-4.83	-3.06
EPS Growth %	-	-2.38%	-0.44%	-0.39%	-0.28%	0.41%	0.6%	0%	0.52%	0.37%
EPS (Basic)	-4.97	-16.80	-24.26	-33.73	-43.05	-25.50	-10.14	-10.10	-4.83	-3.06
Diluted Shares Outstanding	1.28M	1.28M	2.15M	2.22M	2.69M	3.46M	7.12M	8.51M	19.88M	40.82M
Basic Shares Outstanding	1.28M	1.28M	2.15M	2.22M	2.69M	3.46M	7.12M	8.51M	19.88M	40.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.7M	39.97M	70.66M	128.64M	86.3M	158.9M	222.61M	219.64M	129.73M	157.3M
Cash & Short-Term Investments	55.39M	37.66M	69.09M	122.46M	83.52M	154.74M	207.78M	213.72M	123.64M	148.92M
Cash Only	28.59M	7.68M	52.08M	86.37M	76.04M	154.74M	119.14M	155.38M	74.02M	80.23M
Short-Term Investments	26.79M	29.98M	17.01M	36.1M	7.48M	0	88.64M	58.34M	49.63M	68.69M
Accounts Receivable	0	0	0	0	0	0	110K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	2.95	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	88K	235K	613K	1.81M	1.49M	1.48M	8.71M	3M	2.11M	1.65M
Total Non-Current Assets+	0	664K	5.54M	10.96M	17.17M	12.27M	9.77M	40.61M	35.2M	31.36M
Property, Plant & Equipment	0	452K	2.43M	10.42M	16.63M	11.73M	7.6M	38.61M	33.16M	29.04M
Fixed Asset Turnover	-	-	-	-	-	-	1.79x	0.21x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	212K	3.11M	536K	536K	536K	2.16M	2.01M	2.04M	2.32M
Total Assets+	55.7M	40.64M	76.19M	139.6M	103.47M	171.17M	232.38M	260.25M	164.94M	188.66M
Asset Turnover	-	-	-	-	-	-	0.06x	0.03x	-	-
Asset Growth %	-	-0.27%	0.88%	0.83%	-0.26%	0.65%	0.36%	0.12%	-0.37%	0.14%
Total Current Liabilities+	13.92M	6.87M	11.27M	12.48M	18.28M	24.48M	23.6M	22.51M	14.52M	30.26M
Accounts Payable	608K	2.98M	5.07M	3.69M	7.12M	3.27M	4.46M	3.24M	2.03M	4.24M
Days Payables Outstanding	-	19.45K	-	860.29	920.77	304.69	-	-	287.36	629.94
Short-Term Debt	0	0	0	173K	0	0	0	0	0	0
Deferred Revenue (Current)	0	345K	233K	1000K	0	1000K	1000K	0	0	0
Other Current Liabilities	13.06M	2.38M	4.17M	4.91M	3.63M	3.83M	3.12M	8.38M	5.95M	9.37M
Current Ratio	4.00x	5.82x	6.27x	10.31x	4.72x	6.49x	9.43x	9.76x	8.94x	5.20x
Quick Ratio	4.00x	5.82x	6.27x	10.31x	4.72x	6.49x	9.43x	9.76x	8.94x	5.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	61.7M	71.65M	124.18M	1.93M	5.15M	14.6M	568K	26.08M	23.94M	21.16M
Long-Term Debt	0	0	0	859K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	859K	5.15M	2.94M	568K	25.98M	23.94M	21.16M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	61.7M	71.65M	0	215K	0	1.3M	0	96K	0	0
Total Liabilities	75.62M	78.52M	135.45M	14.41M	23.42M	39.08M	24.17M	48.59M	38.46M	51.42M
Total Debt+	0	0	0	1.03M	7.07M	5.15M	2.06M	28.55M	26.27M	24.18M
Net Debt	-28.59M	-7.68M	-52.08M	-85.33M	-68.97M	-149.59M	-117.07M	-126.84M	-47.75M	-56.06M
Debt / Equity	-	-	-	0.01x	0.09x	0.04x	0.01x	0.13x	0.21x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-381.55x
Total Equity+	-19.93M	-37.89M	-59.26M	125.18M	80.05M	132.09M	208.21M	211.67M	126.48M	137.25M
Equity Growth %	-	-0.9%	-0.56%	3.11%	-0.36%	0.65%	0.58%	0.02%	-0.4%	0.09%
Book Value per Share	-15.54	-29.55	-27.57	56.44	29.80	38.15	29.25	24.87	6.36	3.36
Total Shareholders' Equity	-67.51M	-84.36M	-59.26M	125.18M	80.05M	132.09M	208.21M	211.67M	126.48M	137.25M
Common Stock	208K	558K	65.01M	35K	48K	87K	7K	20K	20K	40K
Retained Earnings	-67.71M	-84.94M	-124.26M	-199.06M	-316.28M	-404.57M	-476.76M	-562.74M	-658.75M	-783.45M
Treasury Stock	0	-558K	0	0	0	0	0	0	0	0
Accumulated OCI	-10K	23K	-13K	-5K	1K	0	-45K	-68K	15K	47K
Minority Interest	47.59M	46.47M	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.2M	-20.12M	-43.22M	-70.2M	-92.71M	-56.6M	-77.76M	-97.98M	-94.18M	-100.01M
Operating CF Margin %	-	-	-	-	-	-	-5.71%	-12.1%	-	-
Operating CF Growth %	-	-3.79%	-1.15%	-0.62%	-0.32%	0.39%	-0.37%	-0.26%	0.04%	-0.06%
Net Income	-6.66M	-23.77M	-53.18M	-74.8M	-117.22M	-88.29M	-72.19M	-85.98M	-96.02M	-124.7M
Depreciation & Amortization	0	56K	448K	1.57M	2.82M	3.92M	2.96M	2.41M	2.58M	2.46M
Stock-Based Compensation	764K	1.47M	5.33M	5.96M	14.21M	11.63M	13.37M	7.54M	7.63M	10.52M
Deferred Taxes	0	505K	206K	0	0	0	1.21M	0	0	0
Other Non-Cash Items	108K	-1.16M	-459K	-86K	-277K	-20K	-81K	-18.25M	-2.03M	8.86M
Working Capital Changes	1.59M	2.79M	4.43M	-2.83M	7.75M	16.16M	-23.04M	-3.69M	-6.34M	2.85M
Change in Receivables	0	0	0	0	0	0	-110K	110K	0	0
Change in Inventory	0	0	0	0	0	0	-11.5M	0	0	0
Change in Payables	585K	2.21M	1.58M	-1.61M	3.78M	-3.43M	1.21M	-5.25M	-764K	2.21M
Cash from Investing+	-26.81M	-4.22M	10.55M	-26.76M	24.52M	6.6M	-91.09M	59.16M	9.69M	-16.09M
Capital Expenditures	0	-392K	-2.28M	-7.78M	-4.39M	-899K	-1.28M	-3.02M	-1.51M	-654K
CapEx % of Revenue	-	-	-	-	-	-	0.09%	0.37%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-26.81M	-165K	100K	-18.99M	24.52M	7.5M	-89.81M	600K	0	0
Cash from Financing+	51.59M	3.42M	77.08M	131.51M	57.88M	128.7M	134.99M	74.83M	3.12M	122.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	44.75M	0	-2.42M	-2.17M	8.55M	0	107K	203K	148K	794K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.2M	-20.51M	-45.5M	-77.97M	-97.1M	-57.5M	-79.05M	-100.99M	-95.69M	-100.67M
FCF Margin %	-	-	-	-	-	-	-5.8%	-12.48%	-	-
FCF Growth %	-	-3.88%	-1.22%	-0.71%	-0.25%	0.41%	-0.37%	-0.28%	0.05%	-0.05%
FCF per Share	-3.28	-16.00	-21.17	-35.15	-36.15	-16.61	-11.10	-11.86	-4.81	-2.47
FCF Conversion (FCF/Net Income)	0.66x	0.93x	0.83x	0.94x	0.79x	0.64x	1.08x	1.14x	0.98x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-226.91%	-114.24%	-83.24%	-42.43%	-40.96%	-56.79%	-94.57%
Return on Invested Capital (ROIC)	-	-	-	-	-351.47%	-	-147.19%	-90.74%	-95.67%	-121.68%
Gross Margin	-	-	-	-	-	-	100%	100%	-	-
Net Margin	-	-	-	-	-	-	-530.01%	-1062.28%	-	-
Debt / Equity	-	-	-	0.01x	0.09x	0.04x	0.01x	0.13x	0.21x	0.18x
Interest Coverage	-	-	-	-	-	-	-	-	-	-381.55x
FCF Conversion	0.66x	0.93x	0.83x	0.94x	0.79x	0.64x	1.08x	1.14x	0.98x	0.80x
Revenue Growth	-	-	-	-	-	-	-	-40.57%	-100%	-

Frequently Asked Questions

Growth & Financials

Solid Biosciences Inc. (SLDB) grew revenue by 0.0% over the past year. Growth has been modest.

Solid Biosciences Inc. (SLDB) reported a net loss of $167.1M for fiscal year 2024.

Dividend & Returns

Solid Biosciences Inc. (SLDB) has a return on equity (ROE) of -94.6%. Negative ROE indicates the company is unprofitable.

Solid Biosciences Inc. (SLDB) had negative free cash flow of $133.2M in fiscal year 2024, likely due to heavy capital investments.